Is bmy a buy

**Bristol-Myers Squibb (BMY) does not appear to be a strong buy at this time**, and here's why: 1. **Negative Earnings**: The company has a negative net margin of -100.36% as of March 31, 2024, indicating that it is not generating profits from its operations. 2. **High Debt Levels**: Bristol-Myers Squibb has a high debt-to-equity ratio of 498.45%, which suggests a high level of debt relative to equity. This could lead to increased financial risk. 3. **Stock Performance**: The stock has underperformed compared to the industry and the S&P 500, with a significant decline of 20.5% year-to-date as of July 12, 2024. This indicates a lack of positive momentum. 4. **Market Sentiment**: The consensus rating is "Neutral" with an average price target of $44.4, which is close to the current trading price. This suggests that analysts do not see a strong upside potential. In conclusion, given the company's negative earnings, high debt levels, and underperformance, it is not a compelling buy at this time. Investors should exercise caution and consider these factors before making an investment decision.